This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lee M. Jampol, MD
Chicago

Arch Ophthalmol. 1989;107(2):166-167.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Flach suggests that my estimate of 10 000 new unhappy patients per year (1% of cases) with chronic, visually significant postcataract CME may be an underestimate because the two studies reviewed employed postoperative topical corticosteroid therapy.^1,2 While it is possible that routine postoperative use of corticosteroids decreases the incidence of persistent aphakic or pseudophakic CME, we have no definite evidence to support this hypothesis, in regard to either angiographic or visually significant CME.^3,4 However, virtually all cataract surgeons in the United States do indeed use a postoperative topical corticosteroid. Many patients are given topical corticosteroids indefinitely. Thus, an estimated rate of persistent, visually significant CME of approximately 1% to 2% seems appropriate.

Dr Flach's next point is that the severity of the angiographic CME may not correlate with the patient's visual acuity. In their recently reported study, with small numbers of patients, Flach et al . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?